1. Oncolytics Biotech will attend two major investor conferences next month. 2. CEO Jared Kelly will engage with institutional investors at these events. 3. The company is developing pelareorep as a cancer immunotherapy. 4. Pelareorep has shown promising results in pancreatic and breast cancer studies. 5. Oncolytics seeks strategic partnerships for accelerated drug development.
Participation in investor conferences often boosts visibility and investor interest. Historically, positive news during such events has resulted in stock price increases for biotechs.
Investor conferences are critical for engagement, potentially leading to funding and stock price uplift.
Immediate investor interest from conferences could influence stock price quickly. Similar past events have led to short-term stock rallies for biotech firms.
SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, will participate in two investor conferences next month. CEO Jared Kelly will be meeting with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference. Additional details for both of these events can be found below.
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: Tuesday and Wednesday, September 9 & 10, 2025
Location: Lotte New York Palace Hotel, New York, NY
Event: Lake Street Capital Markets 9th Annual Best Ideas Growth Conference
Date: Thursday, September 11, 2025
Location: The Yale Club, New York, NY
Company management will be participating in one-on-one investor meetings at the conferences. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright or Lake Street Capital Markets representative, or email jpatton@oncolytics.ca.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com
Logo: https://mma.prnewswire.com/media/2408622/5481159/Oncolytics_Biotech_Inc_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-upcoming-investor-conferences-in-september-302540829.html
SOURCE Oncolytics Biotech® Inc.